Islet Amyloid-Induced Cell Death and Bilayer Integrity Loss Share a Molecular Origin Targetable with Oligopyridylamide-Based α-Helical Mimetics  by Kumar, Sunil et al.
Article
Islet Amyloid-Induced Cell Death and Bilayer
Integrity Loss Share a Molecular Origin Targetable
with Oligopyridylamide-Based a-Helical MimeticsGraphical AbstractHighlightsd A series of derivitizable oligopyridylamides is designed and
synthesized
d Oligopyridylamides target a-helical structures of islet amyloid
polypeptide (IAPP)
d Membrane-bound a-helical oligomers of IAPP are associated
with diabetes pathology
d The study suggests a common precursor underpins several
IAPP functionsKumar et al., 2015, Chemistry & Biology 22, 369–378
March 19, 2015 ª2015 Elsevier Ltd All rights reserved
http://dx.doi.org/10.1016/j.chembiol.2015.01.006Authors
Sunil Kumar,
Diana E. Schlamadinger, ...,
Andrew D. Hamilton,
Andrew D. Miranker
Correspondence
andrew.miranker@yale.edu
In Brief
A library of oligopyridylamide-based
helical mimetics was designed and
synthesized to target membrane-
associated a-helical intermediates of islet
amyloid polypeptide, a protein implicated
in type 2 diabetes. Oligopyridylamides
slow the rate of IAPP amyloid assembly
and reduce membrane poration and
toxicity in a rank order that links these
functions.
Chemistry & Biology
ArticleIslet Amyloid-Induced Cell Death and Bilayer
Integrity Loss Share a Molecular Origin Targetable
with Oligopyridylamide-Based a-Helical Mimetics
Sunil Kumar,1 Diana E. Schlamadinger,1 Mark A. Brown,5 Joanna M. Dunn,1 Brandon Mercado,5 James A. Hebda,2
Ishu Saraogi,3 Elizabeth Rhoades,1 Andrew D. Hamilton,4 and Andrew D. Miranker1,*
1Department of Molecular Biophysics and Biochemistry, Yale University, 260 Whitney Avenue, New Haven, CT 06520-8114, USA
2Department of Chemistry, Amherst College, Amherst, MA 01002-5000, USA
3Department of Chemistry, Indian Institute of Science Education and Research, Bhopal, MP 462066, India
4Chemistry Research Laboratory, University of Oxford, 12 Mansfield Road, Oxford OX1 3TA, UK
5Department of Chemistry, Yale University, 225 Prospect Street, New Haven, CT 06520-8107, USA
*Correspondence: andrew.miranker@yale.edu
http://dx.doi.org/10.1016/j.chembiol.2015.01.006SUMMARY
Islet amyloid polypeptide (IAPP) is a hormone cose-
creted with insulin. IAPP proceeds through a series
of conformational changes from random coil to
b-sheet via transient a-helical intermediates. An
unknown subset of these events are associated
with seemingly disparate gains of function, including
catalysis of self-assembly, membrane penetration,
loss of membrane integrity, mitochondrial localiza-
tion, and finally, cytotoxicity, a central component
of diabetic pathology. A series of small molecule,
a-helical mimetics, oligopyridylamides, was previ-
ously shown to target themembrane-bound a-helical
oligomeric intermediates of IAPP. In this study,
we develop an improved, microwave-assisted syn-
thesis of oligopyridylamides. A series of designed
tripyridylamides demonstrate that lipid-catalyzed
self-assembly of IAPP can be deliberately targeted.
In addition, these molecules affect IAPP-induced
leakage of synthetic liposomes and cellular toxicity
in insulin-secreting cells. The tripyridylamides inhibit
these processes with identical rank orders of effec-
tiveness. This indicates a common molecular basis
for the disparate set of observed effects of IAPP.
INTRODUCTION
Protein-protein interactions (PPIs) regulate numerous biological
processes, such as proliferation, differentiation, and apoptosis.
Consequently, misregulation of these interactions contributes
to diseases as diverse as cancer, HIV infection, and many forms
of neurodegeneration. A significant proportion (40%) (Davis
et al., 2007) of PPIs are mediated by a-helical structural motifs.
The structure-based design of small molecules that can stabilize
or disrupt helix-protein interactions with high specificity and
efficacy is a central challenge in medicinal chemistry. Small mol-
ecules that can present functional groups on a preorganizedChemistry & Biology 22, 3framework have been identified that disrupt the helix-protein
recognition surfaces in interactions such as p53/hDM2 (Prabha-
karan et al., 2013; Yin et al., 2005), Bak/Bcl-xL(Ernst et al., 2003),
and the six helix-bundle assembly of GP41 (Ernst et al., 2002).
Plainly, helix-protein interactions are an important and address-
able category of biological target.
Helix-helix interactions can themselves be a component of
pathological gains of function. Such interactions have been
implicated as important to Alzheimer disease, Parkinson dis-
ease, and type 2 diabetes (Davis et al., 2007). In diabetes,
pathological self-assembly occurs in the 37-residue peptide,
islet amyloid polypeptide (IAPP) (Figure 1). IAPP is a hormone,
coexpressed, processed, packaged, and secreted with insulin
by pancreatic b-cells. Its hormonal role is likely autocrine as
IAPP knockout mice display a loss of precision in the pulsatile
nature of insulin secretion (Braun et al., 2012). Importantly, rats
transgenic for the human form of IAPP show a progression of
prediabetic and diabetic symptoms, suggesting that IAPP may
also have a causal role in the etiology of this disease.
Structurally, IAPP is predominantly disordered in aqueous
solution with weak sampling of a-helical states across residues
5–22. Upon interaction with a phospholipid bilayer, IAPP binds,
stabilizes this helical subdomain (Apostolidou et al., 2008; Wil-
liamson et al., 2009), and samples parallel and antiparallel helical
assemblies prior to the conversion of IAPP to an amyloid form
(Nath et al., 2011). Mutagenic analyses of IAPP have shown this
helical region to be important to gains of toxic function in cell cul-
ture (Cao et al., 2013; Magzoub and Miranker, 2012). Whether or
not these states are themselves toxic or are on/off pathways to
toxicity remains an open question. Regardless, these early inter-
actions are important as they either directly lead to the formation
of membrane active toxic oligomers or serve as an off-pathway
pool of protein that can modulate toxic assembly. Perturbation
of these states by smallmolecules is thus desirable for both basic
understanding of the disease and therapeutic lead development.
The structural basis of helix-helix interactions relevant to
function can be characterized by a reduced description: namely,
that of the interactions of side chain residues on one helical face
at positions i, i + 3/i + 4, and i + 7, with corresponding positions
of one or more other a helices. The Hamilton laboratory has
pioneered the development of synthetic small molecules that69–378, March 19, 2015 ª2015 Elsevier Ltd All rights reserved 369
Figure 1. Schematic of Molecules Used in this Work
(A) Synthesis of the analogs of tripyridylamide. Reagents and conditions: (a) 33%HBr in AcOH, reflux, 24 hr; (b) 2 MNH3 in EtOH, 0
C for 30 min and then at room
temperature for 24 hr; (c) NaNO2, Conc. H2SO4, 0
C for 30min and then at 0C for 2 hr; (d) alkyl iodide, Ag2CO3, hexane (dry), 300W, 120C, 12min; (e) Pd(OAc)2,
PPh3, dimethylformamide (DMF, dry), methanol (MeOH, dry), triethylamine (Et3N, dry), CO (g), 100
C, 20 hr; (f) LiOH, tetrahydrofuran (THF)/H2O, room tem-
perature, 30 min; (g) Pd/C, H2 (g), THF, room temperature, 4 hr; (h) compound 1-R, 2-chloro-1-methylpyridinium iodide, dichloromethane (DCM, dry), Et3N (dry),
reflux, 4 hr; (i) Pd/C, H2 (g), THF, room temperature, 4 hr; (j) compound 2-R, 2-chloro-1-methylpyridinium iodide, DCM (dry), Et3N (dry), reflux, 4 hr; (k) DCM/
trifluoroacetic acid (TFA)/triethylsilane (TES) (80:15:5, v/v), room temperature, 3 hr.
(B) Structural representations of the analogs of oligopyridylamides.
(C) Primary sequence of hIAPP used in the study.
(D) A helical wheel representation of the helical subdomain of IAPP. Blue and green represent positively charged and hydrophobic amino acid residues,
respectively.can mimic the placement of R groups at comparable spatial po-
sitions (Cummings and Hamilton, 2010). Thus, disruption using
small molecule protein mimetics can be based on the premise
of mimicking one-half of a helix target interaction. An interaction
might alternatively be allosterically stabilized by binding to the
solvent exposed component of an a-helix-containing complex.
Oligopyridylamide-based mimetics were previously found to
act as antagonists of membrane catalyzed self-assembly of
IAPP (Hebda et al., 2009; Saraogi et al., 2010). Inhibition was
suggested to have been achieved via charge complementarity,
in which the oligopyridylamide scaffold (Figure 1A), derivatized
with carboxylate functionalities, interacts with basic side chain
residues (R11, H18, K1, and N terminus) presented on the
IAPP a-helical surface. The site of contact was confirmed using
nuclear magnetic resonance (NMR) binding studies between a
pentapyridylamide (IS-5) and IAPP. However, the study indicates
that the use of carboxylates was an oversimplification of the
binding interaction. For example, two positive charges, R11
and H18, are separated by two a-helical turns while our
published molecules display three carboxylates over a corre-
sponding distance. In this work, we have therefore conducted
a structure activity analysis of the molecular nature of oligopyri-
dylamide-IAPP interactions. We have improved the synthesis370 Chemistry & Biology 22, 369–378, March 19, 2015 ª2015 Elseviestrategy for this class of molecules and designed and synthe-
sized analogs of tripyridylamide, in which various functionalities
are presented between flanking carboxylates. This systematic
study enables us to gain insight into themolecular basis for inter-
actions involved in self-assembly of membrane-bound a-helical
intermediates of IAPP.
RESULTS AND DISCUSSION
A convergent synthesis-based approach was developed using
a microwave-assisted protocol to facilitate the generation of a
library of tripyridylamides. The bromo-substituted aromatic
imidate was synthesized from 2,6-dichloro-3-nitropyridine in
three steps (Figure 1). This was then selectively O-alkylated
using microwave assistance in the presence of alkyl iodides
and silver carbonate (Figure 1) (Singh et al., 2009). The bromo-
substituted O-alkylated aromatic imidates were converted
to methyl esters in the presence of Pd(OAc)2 under an atmo-
sphere of CO(g) (450 psi, 75C) followed by saponification. Chain
elongation was achieved using iterative amide coupling between
aryl amines and acids using 2-chloro-1-methylpyridinium iodide
(Mukaiyama’s reagent) and subsequent reduction of nitro
groups (see synthesis and characterization in Supplementalr Ltd All rights reserved
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Figure 2. Effect of Oligopyridylamides on the Kinetics of IAPP Amyloid Assembly
(A) Time-dependent ThT fluorescence-based kinetic profiles of lipid-catalyzed IAPP fibrillation alone (black) and in the presence of ADM-1 (blue), IS-5 (brown), or
ADM-3 (red) at a ratio of 10:1 (ligand/IAPP). (Inset) A representative sigmoidal fit used to determine the reaction midpoint, t50.
(B) Summary of reaction t50 for the effect of analogs of tripyridylamide on the kinetics of lipid-free (black) and lipid-catalyzed (light blue) self-assembly.
(C) Dose-dependent effect of ADM-3, ADM-1, ADM-7, and IS-5 on lipid-catalyzed fibrillation.
(D) CD spectra of IAPP in the absence and presence of ADM-3 under lipid-containing conditions.
(E and F) TEM images of lipid-catalyzed 10 mM IAPP after 1 hr in the absence (E) and presence (F) of ADM-3. Lipid-catalyzed conditions: IAPP = 10 mM, ADM-X =
100 mM, ThT = 5 mM, DOPG/DOPC, 1:1, 100 nm = 630 mM. Lipid-free conditions: IAPP = 40 mM, ADM-X = 40 mM, ThT = 20 mM. For TEM, IAPP = 10 mM, ADM-3 =
10 mM, DOPG/DOPC, 1:1, 100 nm = 630 mM. All error bars represent SDs from a minimum of three repeated measurements.Information). The acid labile tert-butyl esters were cleaved using
a trifluoroacetic acid (TFA) cocktail (dichloromethane [DCM]/
TFA/triethylsilane [TES], 80:15:5, v/v/v) in the last step to afford
the series of tripyridylamides as free acids with varying degree
of hydrophobicity on the central pyridine scaffold in nearly
quantitative yields (Figure 1). In comparison with the synthetic
procedure for O-alkylation of bromo imidates reported earlier
(time = overnight and yield = 75%), microwave-assisted protocol
(time = 12 min and yield 75%–93% for various monomers,
Table S1) enabled us to efficiently generate a library of analogs
of O-alkylated bromo imidates. In addition, the O-alkylation in
tandem with carbonylation of bromo imidates makes it a power-
ful tool to generate libraries of oligopyridylamides.Chemistry & Biology 22, 3The kinetic profile of compound effects on lipid-catalyzed and
lipid-free IAPP fibrillation was probed using an exogenous dye,
thioflavin T (ThT), as reporter (Wolfe et al., 2010). ThT binds
specifically to IAPP amyloid fibers without perturbing the kinetics
of amyloid assembly. The kinetic profile for IAPP fibrillation
includes a lag period, a growth phase, and a subsequent
equilibrated phase, in which the protein is predominantly in
the amyloid fiber state (Figure 2A). Analyses in this work are
restricted to the midpoint of the reaction (t50, Figure S1). The
model membrane system used here is an equimolar mixture of
dioleoylphosphatidylglycerol (DOPG) and dioleoylphosphatidyl-
choline (DOPC) extruded into 100 nm large unilamellar vesicles
(LUVs). The presence of a phospholipid surface catalyzes IAPP69–378, March 19, 2015 ª2015 Elsevier Ltd All rights reserved 371
fibrillation and promotes a-helical membrane-bound prefibrillar
structures (Williamson et al., 2009).
Inhibition of lipid-catalyzed IAPP fibrillation is markedly
affected by the elimination of the central carboxylate of our pre-
viously published compound IS-3 (Saraogi et al., 2010). Lipid
membrane catalysis accelerates IAPP fibrillation to a t50 of
0.92 ± 0.02 hr. This is 18 times faster than the lipid-free condi-
tion (t50 = 17.1± 1.2 hr). IS-3, referred to here as ADM-1, pos-
sesses three carboxylate functionalities on its surface. ADM-1
inhibits IAPP fibrillation with a t50 that is 1.7 ± 0.04 times higher
than the control reaction (Figures 2A–2C), in agreement with
our earlier work (t50 = 2.3 ± 0.04 times higher than the control
reaction) (Saraogi et al., 2010). ADM-3, a tripyridylamide with
an ethyl substitution at position R, inhibits IAPP fibrillation with
a t50 that is at least >10-fold higher than the control reaction
(Figure 2). IS-5, a pentacarboxylate pyridylamide, delays IAPP
fibrillation with a t50 that is 3.5-fold higher than the control reac-
tion (IAPP only) at a stoichiometric ratio of 10:1 (IS-5/IAPP,
Figures 2B and 2C), in agreement with our previously published
work (Saraogi et al., 2010). ADM-3 produced the same effect
by delaying IAPP fibrillation with a t50 that is 3.7-fold higher
than the control reaction (IAPP only) at a stoichiometric ratio of
1:1 (ADM-3/IAPP, Figure 2C). In addition, at higher concentra-
tions (up to mM), IS-5’s inhibitory activity maximizes with a t50
that is 3.5-fold higher than the control reaction. In marked
contrast, ADM-3 completely eliminates lipid-catalyzed IAPP
fibrillation. Plainly, trimeric ADM-3 is a far better inhibitor of
lipid-catalyzed IAPP fibrillation than our previously demon-
strated pentameric construct.
ADM-3-inhibited IAPP is nonfibrillar in spectroscopic and
imaging assays. Dose-dependent effects of ADM-3 on the t50
of fibrillation exclude the concern of intensity-based artifacts in
the ThT assay (Figure 2C). Moreover, both circular dichroism
(CD) and transmission electron microscopy (TEM) based results
corroborate well with the ThT assay in terms of exhibiting inhib-
itory activity of ADM-3 on IAPP fibrillation. IAPP exhibits predom-
inantly a-helical structure in the presence of lipid membrane
(LUVs, DOPG/DOPC, 1:1, 100 nm) characterized by two minima
at 208 and 222 nm in the CD spectrum (Figure 2D). The
conformation of IAPP alone switches from a-helical to b-sheet
in 1 hr. In marked contrast, IAPP remains in an a-helical state
in the presence of ADM-3 after 2 hr at a stoichiometric ratio (Fig-
ure 2D). TEM showed IAPP fiber formation after 1 hr (Figure 2E);
however, no fibers were observed in the presence of ADM-3
even after 2 hr at an equimolar ratio (Figure 2F). As a control,
denoted by ADM-3*, a mixture of monomeric building blocks
for ADM-3 (Scheme S2) has no effect on lipid-catalyzed IAPP
fibrillation, indicating the importance of functionalities at suitable
spatial distance and orientation. The tripyridylamides have no
effect on ThT fluorescence intensity by themselves (Figure S2).
Thus, the observation of inhibition by ADM-3 is robustly
observed across several complementary assays.
The ethyl carbon of R occupies a site of specific importance to
lipid-catalyzed IAPP assembly. This is evident by first comparing
the inhibitory effect of ADM-3 and ADM-2 on IAPP fibrillation.
The former inhibits with a t50 that is >10-fold higher than the
control reaction (Figure 2B). In marked contrast, a single carbon
loss to a methyl R group (ADM-2) is strongly detrimental. The
effectiveness of ADM-2 is 2.9 ± 0.02 fold inhibitory relative to372 Chemistry & Biology 22, 369–378, March 19, 2015 ª2015 Elseviethe control reaction. Substitution to a longer chain at R
(ADM-4) preserves the ethyl carbon, and effectiveness is also
maintained. In addition, a long aliphatic chain substitution at
position R (ADM-5) is more inhibitory than ADM-2 (Figure 2B).
Interestingly, inhibitory activity of ADM-5 is weakened relative
to the ethyl (ADM-3) and butyl (ADM-4) substituted compounds.
We conjecture this is due to self-association of the aliphatic
chains, which could decrease its effectiveness.
The introduction of branched substituents at ethyl carbon
(ADM-6 and ADM-8) diminish the inhibitory activity towards
IAPP fibrillation compared with ADM-3 (Figure 2B). This is re-
flected by the decrease in t50 of ADM-6 and ADM-8-containing
reactions in comparison with ADM-3. In addition, the introduc-
tion of branched substituents at the methyl position (ADM-7 to
ADM-9) also produced similarly diminished effects on IAPP fibril-
lation. This suggests the formation of steric clash for branched
substitution at methyl and ethyl positions of R. It is worth noting
that while inhibitory activity is diminished compared with ADM-3,
thesemolecules are still more potent inhibitors of IAPP fibrillation
than ADM-1. The sensitivity of effectiveness to branching sug-
gests a close-packed interaction of tripyridylamides with IAPP.
To gain mechanistic insight into the role of phospholipid
surface, kinetic assays were conducted in solution with no lipid
(Figure 2B). Tripyridylamides in general were ineffective against
IAPP fibrillation, except ADM-5, which was a modest inhibitor
of IAPP fibrillation at a stoichiometric ratio of 1:1 (tripyridyla-
mide/IAPP). We have shown earlier that IS-5 acts as an agonist
to IAPP fibrillation (lipid free, Figure 2B) (Hebda et al., 2009;
Saraogi et al., 2010). Here, ADM-3, which is 40% smaller and
has 60% fewer anionic charges than IS-5, shows modest inhibi-
tion, indicating that one or both of these changes are responsible
for oligopyridylamide to act instead as agonist in lipid-free con-
ditions. We earlier conjectured that IS-5 mimics the membrane
surface and catalyzes IAPP fibrillation. Tripyridylamides, on the
other hand, have only small effects on IAPP fibrillation under
lipid-free conditions even at higher stoichiometric ratios (2:1,
tripyridylamide/IAPP). This suggests that the mechanism is
more nuanced than simply a competition with membrane sur-
face. ADM-5 is an exception to this observation. The presence
of self-associated ADM-5 (see below) may contribute to its
capacity to act as an inhibitor even in the absence of a lipid sur-
face catalyst.
ADM-3 is an effective inhibitor of membrane-associated elon-
gation processes. Elongation was directly assessed by acceler-
ating the IAPP self-assembly reaction using preformed fibers
as seed. This bypasses primary nucleation processes, charac-
terized by shortening of the lag phase (Figure 3). Here, lipid
surface-catalyzed IAPP fibrillation was accelerated to a t50
7.7 ± 0.3 fold faster by the addition of 1% seeds to a standard
reaction (Figure 3A). Under this condition, the reaction is com-
plete while still in the lag phase of the seed-free control. At an
equimolar ratio, addition of ADM-3 slows down the elongation
process to a t50 that is 8.1 ± 0.4 fold slower than the seeded re-
action (Figure 3A). At a stoichiometric ratio of 10:1 (ADM-3/IAPP),
IAPP amyloid self-assembly is wholly arrested. In marked
contrast, the equivalent reactions performed in the absence of
lipid give no inhibition at 1:1 and onlymodest inhibition of seeded
assembly at 10:1, ADM-3/IAPP (Figure 3B). We conjecture
that ADM-3 binds to a-helical intermediates of prefibrillar IAPPr Ltd All rights reserved
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Figure 3. Effect of ADM-3 on the Kinetics of Seeded IAPP Fibrillation
Representative kinetic profiles of seeded reactions measured under lipid-
catalyzed (A) and lipid-free (B) conditions. The x axes are expressed as re-
action time divided by the reaction t50 of an unseeded control. (Inset) Statistics
of repeats of experiments shown in (A) and (B). For lipid-catalyzed conditions:
IAPP = 10 mM, DOPG/DOPC, 1:1, 100 nm = 630 mM, seed = 1% (w/w), ThT =
5 mM. For lipid-free conditions: IAPP = 30 mM, seed = 5% (w/w), ThT = 15 mM.
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Figure 4. Oligopyridylamides Affect IAPP-Mediated Toxicity
(A) Representative toxicity of 13 mM IAPP with and without the cointroduction
of equimolar amounts of the indicated compound (open bars). Toxicity of
13 mM compound alone (no IAPP) is also shown (filled bars). Error bars reflect
variability across 4–8 technical replicates within a single execution of the
assay.
(B) Statistics of relative toxicity from repeated independent execution of
toxicity assays shown in (A). Data are expressed as toxicity in the presence of
compound relative to toxicity of IAPP alone measured at the same time on
the same batch of cells.
(C) Rescue from 13 mM IAPP toxicity as a function of the indicated concen-
tration of ADM-3.structures and attenuates their access to mature fibers. The
greater sampling of a-helical states on the membrane surface
facilitates the increase in apparent effectiveness of the helix
targeted small molecules.
Lipid surface-catalyzed amyloid formation serves as a down-
stream readout of events that may be associated with cell
toxicity (Hebda et al., 2014). We therefore investigated the ca-
pacity of ADM-3 to affect cell toxicity andmembrane permeation
gains of function. ADM-3 rescues IAPP-mediated cytotoxicity
(Figure 4). Toxicity is readily induced in an established pancreatic
b-cell model, INS-1 (Huang et al., 2007). In the presence of 13 mM
IAPP, the viability of INS-1 cells is reduced to 64% ± 3% (36% ±
3% toxicity) compared with addition of IAPP-free vehicle. Com-
pounds alone are nontoxic under these conditions and do not
interfere with the colorimetric assay (Figure S4). ADM-3, the
most effective inhibitor of IAPP fibrillation, completely rescues
INS-1 cell toxicity at a stoichiometric ratio of 1:1 (Figures 4A
and 4B). ADM-1 (IS-3) and IS-5 rescued toxicity by 43% ± 9%
(ADM-1/IAPP, 1:1) and 94% ± 7% (IS-5/IAPP, 1:1), respectively
(Figures 4A and 4B). Dose-dependent analysis of ADM-3 reveals
it to function at substoichiometric concentrations with 100%
rescue evident at 1:0.5, IAPP/ADM-3. Clearly, the effectiveness
of ADM-3 on lipid-catalyzed fiber formation is reflected in its
capacity to rescue INS-1 cells from IAPP-induced toxicity.
Membrane poration at the mitochondrial membrane is a
potential contributor to IAPP-mediated cell toxicity. Hence,
in vitro leakage may serve as a complementary assay for cell
toxicity (Last and Miranker, 2013). Liposome leakage kinetics
were used to assess the binding interaction between mem-
brane-bound a-helical intermediates of IAPP and tripyridyla-
mides (Figure 5). Our assay uses 100-nm-diameter, unilamellar
extruded vesicles made from 100% DOPG. Fluorescein dextran
at 70 kDa was encapsulated during extrusion. This size
dextran has previously been shown not to escape from IAPP
permeabilized vesicles. The kinetics of leakage was probed
by quenching the fluorescence using DPX (p-xylene-bis-pyridi-
nium bromide, 400 Da). This results in well-defined, single
exponential profiles, in which 100% leakage is observed.
The leakage rate constant for 4 mM IAPP was 9.3 ± 1.1 3Chemistry & Biology 22, 3104 s1, which is within the range of our published report (Fig-
ure 5) (Last et al., 2011).
Small molecules that affect fiber formation and toxicity also
affect the leakage competence of IAPP. The rate constant for
liposome leakage induced by IAPP in the presence of ADM-3
(Figure 5A) was decreased by a factor of 1.6 ± 0.3 and 3.2 ±
0.4 at a stoichiometric ratio of 1:1 (ADM-3/IAPP) and 10:1,
respectively (inset, Figure 5B). On the other hand, at 10:1
(ligand/IAPP), ADM-1/IS-3 and IS-5 delay the kinetics of IAPP-
mediated leakage by a factor of 1.1 ± 0.1 and 2.2 ± 0.4, respec-
tively (Figure 5B). To assess the completeness of the leakage
reaction, magainin 2, an antimicrobial peptide from Xenopus,
was added to the wells after 90 min. A significant decrease in
the fluorescence intensity is apparent for the solutions without
IAPP. In contrast, no significant changes in fluorescence are
observed for IAPP containing samples, indicative of the com-
plete permeabilization of fluorescein encapsulated liposomes.
As a further control, fluorescein-encapsulated liposomes were
assayed with oligopyridylamides only. No leakage was observed
(Figure S3). Plainly, the helical targeted oligopyridylamides have
the capacity to diminish membrane permeation.
A common precursor underpins poration, fiber formation, and
toxicity. ADM-3 and three other molecules are shown here to
inhibit IAPP-induced membrane permeabilization as well as
lipid-catalyzed IAPP amyloid assembly. Moreover, these mole-
cules are capable of rescuing cytotoxicity induced in INS-1 cells.
Importantly, the rank order for molecules affecting all three
processes is the same: ADM-3 > IS-5 > ADM-7 > ADM-1. This
suggests a common, membrane-bound helix conformation
underpins all three gains of function. Our observed correlation
is at odds with a recently published report (Cao et al., 2013),
which suggests that a-helical structure is not required for mem-
brane leakage and that membrane leakage is not directly related
to toxicity. We matched the conditions at or near the P/L ratio69–378, March 19, 2015 ª2015 Elsevier Ltd All rights reserved 373
A B
Figure 5. Attenuation of IAPP-Mediated Liposome Leakage
(A) Representative assessment of leakage competence performed using
fluorescein dextran-encapsulated liposomes. At t = 0, 200 mM of DOPG LUVs
are exposed to the soluble quencher DPX only (control), or with addition of
4 mM IAPP (black), or with addition of 10:1 of the indicated compound/IAPP
(colored). The fully leaked response and scale are established with 20 mM
magainin 2.
(B) Statistics from repeat analysis of single exponential fits to leakage data
shown in (A). Data are expressed relative to IAPP only control (black). (Inset)
Dose dependence of ADM-3.
All error bars represent SDs from a minimum of four repeated measurements.used in that work: 1:6.7. In response to the addition of liposomes,
we observe no change in CD signal (Figure 6B; Figures S5A and
S5B), no change in the linear diffusion (Figure 6C), and no change
in NMR chemical shifts (Figure 6D; Figure S5C). This suggests
that it is the absence of membrane binding that results in a
lack of a change in secondary structure. Observed leakage
in that work is measured at two time points: 10 min and
2 days. Reported observables are significant but often fractional210 220 230 240 250
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example, 30 mM human IAPP (hIAPP) shows 30% leakage at
10 min and 60% after 2 days. This suggests the presence of
a dead-time event. Our assay gives full, single exponential pro-
files from 0% to 100% leaked. The assay used by Cao et al. likely
reports on a leakage process that is not the same as ours.
Our own efforts using mutagenesis suggest that membrane-
bound a-helical substates are associated with several solution
and cellular gains of function, including localizing to mitochon-
dria (Magzoub and Miranker, 2012). Such work does not
implicate a-helical states directly but underpins the idea that
manipulation of the helical assemblies can affect gains of func-
tion. Such manipulation includes direct interaction with helical
subdomains or binding to one or more intermediates down-
stream of the helical states. Toxic oligomers that are neither
amyloid fiber nor monomeric precursor have been detected,
for example, by immunochemical methods (Kayed et al., 2003)
and crystallography (Laganowsky et al., 2012). The small mole-
cules synthesized here are designed to interact with the a-helical
subdomain. As a result, we assert that our observations support
the view that leakage-competent a-helical oligomeric states pro-
vide either the conditions from which toxic species arise or are
directly responsible for IAPP-mediated toxicity.
The crystal structure of tert-butyl analogs of ADM-5 and ADM-
7 were determined (Figure 7). The structures adopt a rod-like
elongated conformation with a stable curved backbone stabi-
lized by the bifurcated hydrogen bonding (Figure 7). The crystal
packing of ADM-5 shows self-assembly possibly assisted by
the aliphatic chain (Figure 7A). This possibility was confirmed
under our lipid-free, kinetic assay conditions by 1D, 1H NMR.
The 1H peaks in spectra of ADM-5 were broad (Figures 7D and.0 7.8 7.6
ppm)
V17
F15
T6
T4
.0 7.8 7.6
L12
Y37
L16
only
C:DOPG (3:1)
:6.7)
Figure 6. Characterization of IAPP Mem-
brane Binding under Alternate Conditions
(A and B) CD spectra of 60 mM hIAPP (A) or rat
IAPP (B) in the absence (black) and presence (red)
of liposomes at the indicated stoichiometry of
DOPC/DOPG and with P/L = 1:6.7 (IAPP/lipid).
(C) Normalized fluorescence autocorrelation
curves for 100 nM rat IAPPRG. Shown are protein
alone (black) and in the presence of DOPC/DOPG
(3:1) liposomes at the indicated P/L. Shifts of
curves to the right are indicative of binding to the
liposomes. Red and black are obscured by the
green points.
(D) NMR (15N HSQC) of 50 mM rat IAPP in the
absence (black) or presence (red) of lipid bilayer at
1:6.7 (IAPP/lipid), and DOPC/DOPG at 3:1. (Inset)
A 3-fold magnification of resonances from the
a-helical subdomain (L12, L16), and the C termi-
nus (Y37). Ellipticity in (A) and (B) are in units of deg
cm2 dmol1 res1. Buffer conditions (A–C): 20 mM
Tris-HCl, 100 mM NaCl (pH 7.4). (D) As in (A–C),
but at pH 6.5 here, and pH 7.5 in supplement
(Figure S5).
r Ltd All rights reserved
Figure 7. Atomic Structures of Tripyridyla-
mides
(A) A crystallographic dimer of the tert-butyl ester
analog of ADM-5.
(B) Overlay of crystal structure models of ADM-3
and ADM-7. ADM-3 is derived from the crystal
structure of tert-butyl ester ADM-5, with tert-butyl
ester and excess R group atoms removed (blue).
Crystals were not obtainable for ADM-3. ADM-7 is
also shown with tert-butyl ester groups removed.
Alignment was performed using only atoms from
one of the pyridyl rings.
(C) Side-on, space-filled views of the structures
shown in (B).
(D) Comparison of 1D 1H NMR spectra of the
aromatic region (full spectra in Figure S5D) of
ADM-3, ADM-5, and ADM-7 under lipid-free,
kinetic assay conditions (see Figure 2).S5D). In marked contrast, splitting of proton peaks in ADM-3 and
ADM-7 was readily resolved. We conjecture that the dynamic
self-assembly of ADM-5 (Figure 7D) attenuated the accessibility
of the monomer to inhibit IAPP fibrillation and reduced its inhib-
itory activity in comparison with ADM-3 and ADM-4. A model of
ADM-3 can be derived from ADM-5 by deletion of atoms (Fig-
ure 7B). ADM-3 presents the side chains on one face, which is
the potential complementary recognition surface for the mem-
brane-bound helical structure of IAPP (Figure 7B, blue).
ADM-7, where cyclohexane is substituted at position R, affects
the positioning of adjacent side chains probably due to the steric
hindrance (Figures 7B and 7C). We speculate that the range of
the conformations accessible for COOH functional groups are
limited by the steric clash offered by the central bulky group
(here, cyclohexane), which might contribute to their lower inhib-
itory activity towards IAPP fibrillation. In summary, a series of
analogs of tripyridylamide was designed and synthesized with
varying functionalities presented on its surface. The selection
process was sensitive to formation of an optimal complementary
surface to side chain residues of the a-helical domain of IAPP.
The inhibitory activity of tripyridylamides is strongly sensitive to
the selection of the functionality at the R position on the central
pyridyl moiety. Indeed, structure-based design enabled us to
create a trimeric construct that wholly eclipsed the molar activity
of our previously published pentapyridyl amide (Hebda et al.,
2009; Saraogi et al., 2010). The study lays a foundation for
designing putative small molecule inhibitors of membrane-
bound a-helical oligomeric intermediates, which have been
suggested as relevant not only to type 2 diabetes but also to
Alzheimer’s and Parkinson’s diseases.Chemistry & Biology 22, 369–378, March 19, 2015SIGNIFICANCE
Self-assembly of disease-specific
proteins into ordered fibrillar aggre-
gates is a hallmark of many clinical
conditions. IAPP, a 37-residue peptide
hormone cosecreted with insulin,
proceeds through a series of confor-
mations starting with weakly helical
states in solution to membrane-bounda-helical forms that eventually lead to b sheet rich, filamen-
tous aggregates. One possibility relevant to diabetes is that
some subset of this dynamic and heterogeneous ensemble
of membrane-bound states is directly or indirectly respon-
sible for the several pathological gains of function, including
membrane translocation, membrane poration, mitochon-
drial localization, and cytotoxicity. A structure–activity rela-
tionship study, using a designed small molecule template,
has been used to gain insight. The template allows linking
of the membrane-bound IAPP ensemble to amyloidogene-
sis, membrane leakage, and cytotoxicity.EXPERIMENTAL PROCEDURES
Materials
Unless otherwise indicated, all IAPP used in this work is the wild-type,
human sequence. hIAPP was synthesized by t-Boc methods and purified
by Genscript and Elim Biopharmaceuticals. Uniformly labeled with 15N,
wild-type rat IAPP was prepared recombinantly as described previously
(Williamson and Miranker, 2007). ThT was purchased from Acros Organics.
Lipids (DOPG and DOPC) were purchased from Avanti Polar Lipids.
The 96-well plates (black, with flat bottom) were bought from Greiner
Bio-One. All of the chemicals were purchased from commercial suppliers
and used without further purification. Silica plates (w/UV254, aluminum
backed, 200 mm) and silica gel (standard grade, particle size = 40–
63 mm, 230 3 400 mesh) for flash column chromatography were purchased
from Sorbent Technologies. Dry solvents were purchased from Sigma-
Aldrich or VWR. 2,6-Dichloro-3-nitropyridine, alkyl iodides, Et3N (dry),
2-chloro-1-methylpyridinium iodide, tert-butyl bromoacetate, TFA, and
TES were purchased from Sigma Aldrich. The microwave-assisted syn-
thetic steps were performed in 5 ml vials (Biotage) using a Biotage
Initiatior Classic Synthesizer.ª2015 Elsevier Ltd All rights reserved 375
Preparation of IAPP
IAPP (2 mg) was solubilized in 7 M guanidinium hydrochloride. The solution
was filtered (0.2 mm) and transferred to a silica C-18 spin column, 50–450 ml
loading, 30–300 mg capacity (The Nest Group), washed twice with water
(400 ml each) followed by 10% acetonitrile in water, 0.1% formic acid (v/v),
and then eluted into 200 ml of 50% acetonitrile in water, 0.1% formic acid
(v/v). The concentration of IAPP (oxidized form) was calculated using absor-
bance measurements at 280 nm (ε = 1400 M1 cm1). The IAPP solution
was divided into several aliquots (20–50 ml, 1–2 mM), lyophilized, and stored
as a white solid at –80C. Fresh stock solution of IAPP was prepared in water
for each experiment.
Preparation of Rat IAPPRG
IAPP was fluorescently labeled on its amino terminus with rhodamine green
(RG) succinimidylester by adding a 3.5 molar excess to the peptide in a
pH 7.4, 100 mM sodium bicarbonate solution and incubating for 4 hr at
room temperature. Free dye was separated from labeled peptide using a
C-18 reverse-phase analytical high-performance liquid chromatography
(HPLC) column (Grace Vydac). Fractions containing labeled IAPP, IAPPRG,
were pooled, lyophilized, and stored at –80C. For measurements, samples
were solubilized with 20 mM Tris (pH 7.4), 100 mM NaCl buffer.
Preparation of Unilamellar Vesicles
LUVs were prepared from mixture of DOPG/DOPC at ratios specified in the
text. The solution of DOPG and DOPC in chloroform (20 mg ml1 each) was
first mixed and then dried with argon for 1 hr followed by drying on a lyophilizer
for 4 hr. The mixture was hydrated in 100 mM KCl, 50 mM sodium phosphate,
and pH 7.4 for 20 min. A 20 mg ml1 solution of lipid in buffer was passed
21 times through 100 nm diameter filters (Whatman, GE Healthcare). The
phospholipid content of the final material was also confirmed bymeasurement
of total phosphorous (Chen et al., 1956).
Kinetic Assay
Unless otherwise stated, kinetic reactions were conducted in buffer containing
liposome (630 mM, DOPG/DOPC, 1:1, size = 100 nm) and 20 mMThT in a black
96-well plate. This was followed by addition of the small molecule dissolved
in DMSO (final DMSO concentration: 0.5%, v/v). Fiber formation was initiated
by addition of IAPP stock solution (final concentration: 10 mM). Final volume
in each well was 200 ml. The kinetics of IAPP fibrillation was monitored by
ThT fluorescence (excitation 450 nm and emission 485 nm) using a FluoDia
T70 fluorescence plate reader (Photon Technology International). The data
were blank subtracted and renormalized to the maximum intensity of reactions
containing only IAPP.
Reaction profiles were fit using the built-in sigmoidal fit on Origin 5.0 sepa-
rately for each run. This was used to extract separate t50 (time required to
reach 50% change in fluorescence) from which average deviation and SD
were calculated. All presented fits were normalized for clarity. Kinetic assays
under lipid-free condition were repeated in the same way as mentioned
above, except there is no lipid present. Error bars shown in this work represent
SDs from the mean of three or more repeat experiments.
Electron Microscopy
IAPP (10 mM) was incubated in buffer (100 mM KCl, 50 mM sodium phosphate
[pH 7.4]) under lipid-catalyzed amyloid formation conditions (DOPG/DOPC,
1:1, 630 mM, d = 100 nm) both in the absence and presence of ADM-3. Aliquots
of these samples were then applied on glow-discharged (25 mA and 30 s)
carbon-coated 300-mesh copper grids for 1 min and then dried. Grids were
then negatively stained for 1 min with uranyl acetate (2%, w/v) and dried.
Micrographs of grids were examined on a Phillips Tecnai 12 TEM at 120-kV
accelerating voltages. All conclusions drawn from images in this work include
at least one repeat in which the sample identity was withheld from the investi-
gator preparing and analyzing images.
CD
The stock solution of IAPP (1–2 mM) in water was diluted to 25 mM IAPP in
100 mM KCl and 50 mM sodium phosphate at pH 7.4 and premixed with
LUVs (1200 mM, DOPG/DOPC, 1:1, 100 nm) before measuring the spectra.
CD spectra were collected at 0.5-nm intervals from 200 to 260 nm with 10-s376 Chemistry & Biology 22, 369–378, March 19, 2015 ª2015 Elsevieaveraging timewith an average of four repeats. The CD spectra in the presence
of ADM-3 were recorded using a similar method as described above, except in
the presence of ADM-3 at a stoichiometric ratio of 1:1 (ADM-3/IAPP). The CD
spectra recorded for 60 mM IAPP in Figure 6 (main text) and Figure S5 were
conducted in 100 mM NaCl and 20 mM Tris-HCl (pH 7.4) in the absence and
presence of LUVs (400 mM, DOPG/DOPC, 1:3, 100 nm). IAPP was preincu-
bated with LUVs for 10–15 min before recording the spectra.
NMR Spectroscopy
50 mM 15N-labeled rat IAPP lipid-free NMR samples were prepared in either
20 mM Tris, 100 mM NaCl, 10% D2O (pH 6.5) or 20 mM Tris, 100 mM NaCl,
10% D2O (pH 7.4). 50 mM
15N-labeled rat IAPP NMR samples with liposomes
were prepared under matched buffer conditions described above. All data
were obtained on an Agilent 800 MHz spectrometer equipped with a triple-
resonance HCN cold probe. All experiments were performed using an inbuilt
15N-HSQC pulse sequence using matched parameters. The mixing time
for the 15N-HSQC NMR was 175 ms. The amide cross-peaks of amino acid
residues in HSQC NMR spectra were previously assigned (Williamson and
Miranker, 2007). Data processing was conducted using nmrPipe (Delaglio
et al., 1995) and plotted using Sparky (Goddard and Kneller, 2004).
Liposome Leakage Assay
The kinetics of liposome leakage induced by IAPP was monitored on a
QuantaMaster C-61 fluorescence spectrometer (Photon Technology Interna-
tional) at 25C. The excitation and emission were observed at 480 nm and
526 nm, respectively, with 3-nm slit widths. The stock solution of IAPP used
in the measurements was kept in water at a concentration of 1–2 mM. The
stock solution of water-soluble quencher, DPX (p-xylene-bis-pyridinium
bromide) was prepared in buffer (100 mM KCl, 50 mM NaPi [pH 7.4]) at a
concentration of 100 mM. The small molecules used in leakage assay were
dissolved in DMSO with a concentration range 10–20 mM. The final con-
centration of dye encapsulating liposome, hIAPP, and small molecules were
200, 4, and 40 mM, respectively. The final buffer concentration was corrected
using a higher concentration of buffer to keep the osmolality balanced.
The final concentration of DMSO used in the assay was less than 0.4%.
The control sample contained everything except IAPP. To determine the
leakage rate constant, first, the fluorescence was normalized and corrected
by subtracting it from normalized fluorescence of control reaction. The
corrected fluorescence was fit using the equation given below (using Matlab).
All the experiments were performed in triplicate and the error values presented
are SDs.
a  expð  b  xÞ+ c
where b is the leakage rate constant.
Fluorescence Correlation Spectroscopy
Fluorescence correlation spectroscopy measurements were made on a
laboratory-built instrument using a 488 nm diode-pumped solid-state laser
for excitation (Coherent), as described previously (Sevcsik et al., 2011). Laser
powers between 5.0 and 5.3 mWwere measured prior to the laser entering the
microscope. The fluorescence emission was collected through an objective
and spectrally separated from the laser excitation using a Z488RDC long-
pass dichroic and an HQ600/200M band-pass filter. The resulting fluores-
cence emission was focused onto the aperture of a 50-mm-diameter optical
fiber coupled to an avalanche photodiode. The autocorrelation curves were
created by a digital correlator (Flex03LQ-12, Correlator.com).
For measurements, 100 nM IAPPRG and liposomes were mixed by pipette in
glass-bottomed 8-well chambers (Nunc) passivated with polylsine conjugated
polyethylene glycol solution and incubated 5 min prior to measurement
(Middleton and Rhoades, 2010). For each lipid concentration, 30 traces of
10 s duration were measured.
Cytotoxicity Assay
Rat insulinoma INS-1 cells (832/13, Dr Gary W. Cline, Department of Internal
Medicine, Yale University) were cultured at 37C and 5% CO2 in phenol red
free RPMI 1640 media supplemented with 10% fetal bovine serum, 1% peni-
cillin/streptomycin (all from Life Technologies), and 2% INS-1 stock solution
(0.5 M HEPES, 100 mM L-glutamine, 100 mM sodium pyruvate, and 2.5 mMr Ltd All rights reserved
b-mercaptoethanol). Cells were passaged upon reaching 95% confluence
(0.25% Trypsin-EDTA, Life Technologies), propagated, and/or used in exper-
iments. Cells used in experiments were pelleted, and cells were resuspended
in fresh media with no Trypsin-EDTA.
Cell viability was measured using the Cell-Titer Blue (CTB) fluorescence-
based assay. CTB reagent (Promega) comprises nonfluorescent resazurin,
which is metabolically reduced to fluorescent resorufin in living cells. Cells
were plated at a density of 20,000 cells well1 (500 ml well1) in 24-well plates
(BD Biosciences). After culturing for 48 hr, media were replaced with fresh
media containing hIAPP and small molecules premixed at the desired con-
centration. Cells were incubated at 37C and 5% CO2 with peptide and small
molecules for an additional 48 hr. After the incubation period, CTB reagent
(100 ml) was added to each well and incubated at 37C and 5% CO2 for
3–3.5 hr. Fluorescence of the resorufin product was measured on a FluoDia
T70 fluorescence plate reader (Photon Technology International). All solutions
included 0.13% DMSO and 0.65% H2O to account for the addition of peptide
and small molecule vehicle to sample wells. Wells that included vehicle but not
peptide or small molecule served as the negative control (100% viable), and
wells containing 10% DMSO were the positive control (0% viable). Percent
toxicity was calculated using the following equation:
Percent toxicity= 100 100$
hSi  hPi
hNi  hPi

Each independent variable is the average fluorescence of 4 technical
replicates from the negative control (N), positive control (P), and 2, 3, 4, or 8
technical replicates for samples (S, see manuscript Figure 4).
NMR Spectroscopy (Small Molecules)
The NMR spectra of small molecules (both 1H NMR and 13C NMR) were re-
corded on 400, 500, and 600 MHz Agilent spectrometers. The deuterated
solvents used for all the compounds (except ADM-1–ADM-9) was CDCl3.
For compounds ADM-1 to ADM-9, (CD3)2SO was used. Chemical shifts in
NMR spectra are recorded in ppm and are calibrated against the residual
solvent signals of CDCl3 [d (H) = 7.26], (CD3)2SO (d = 2.50). Splitting patterns,
which were difficult to interpret, were recorded as multiplet (m) or broad (b).
MestReNova (version 8.1.0) was used to integrate and process the NMR
spectra.
Molecular Weight Determination (Small Molecules)
Mass spectra were obtained using either MALDI-TOF Voyager DE Pro
(Yale, CBIC Center) or University of Illinois Mass Spectrometry Facility. High-
resolution electrospray ionization mass spectra were obtained using the
Waters Synapt G2-Si ESI MS mass spectrometer. For MALDI-TOF, trans-2-
[3-(4-tert-butylphenyl)-2-methyl-2-propenylidene] malononitryile from Sigma-
Aldrich was used as the matrix. The MALDI-TOF spectra were collected using
an N2 laser (337 nm wavelength), with an average of 500 shots per sample
with a delayed time of 100 ns between each shot. Elemental analyses of
tripyridylamides (ADM-2 to ADM-9) were carried out using PerkinElmer 2400
Series II CHNS/O Elemental Analyzer.
Purification of Small Molecules Using Flash Column
Chromatography
The small molecules (except ADM-2 to ADM-9 and series 3) were purified us-
ing flash column chromatography. The solvent mixtures used for thin-layer
chromatography and column chromatography were hexane/ethylacetate
(80:20, v/v) and (60:40, v/v) for monopyridyls and oligopyridyls, respectively.
The purification of small molecules was visualized using a UV lamp.
HPLC Purification
HPLC purification of small molecules was carried out on Varian ProStar using
VYDAC reverse-phase columns (4.6 3 100 mm, 1 ml min1, analytical; 10 3
100 mm, 3 ml min1, semiprep.). The mobile phase was composed of (A)
5% ACN, 95% H2O, 0.1% TFA (v/v) and (B) 95% ACN, 5% H2O, and
0.08% TFA (v/v). The solvent gradient used for compound purification was
0%–100% solvent B in solvent A for 10 min at a flow rate of 3.0 ml min1 fol-
lowed by 100% solvent B for 25 min (1 ml min1 for analytical). The solvent
elution was monitored at 220 nm.Chemistry & Biology 22, 3ACCESSION NUMBERS
The Cambridge Crystallographic Data Center (CCDC) accession numbers for
the tert-butyl analog of ADM-5 and ADM-7 reported in this paper are 1005071
and 1005072 respectively.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
for synthesis of oligopyridylamides, 153 figures, two schemes, and five tables
and can be found with this article online at http://dx.doi.org/10.1016/j.
chembiol.2015.01.006.
ACKNOWLEDGMENTS
This research was supported, in part, by NIH GM094693 to A.D.M. and an
American Diabetes Association mentor-based postdoctoral fellowship to
D.E.S. We are thankful to the laboratories of Prof. Nilay Hazari and Prof. David
A. Spiegel (Chemistry Department, Yale University) for providing instruments
and space to perform carbonylation and microwave-based reactions en route
to the synthesis of oligopyridylamides.
Received: September 3, 2014
Revised: December 10, 2014
Accepted: January 13, 2015
Published: March 5, 2015
REFERENCES
Apostolidou, M., Jayasinghe, S.A., and Langen, R. (2008). Structure of alpha-
helical membrane-bound human islet amyloid polypeptide and its implications
for membrane-mediated misfolding. J. Biol. Chem. 283, 17205–17210.
Braun, M., Ramracheya, R., and Rorsman, P. (2012). Autocrine regulation of
insulin secretion. Diabetes Obes. Metab. 14, 143–151.
Cao, P., Abedini, A., Wang, H., Tu, L., Zhang, X., Schmidt, A.M., and Raleigh,
D.P. (2013). Islet amyloid polypeptide toxicity and membrane interactions.
Proc. Natl. Acad. Sci. USA 110, 19279–19284.
Chen, P.S., Toribara, T.Y., andWarner, H. (1956). Microdetermination of phos-
phorus. Anal. Chem. 28, 1756–1758.
Cummings, C.G., and Hamilton, A.D. (2010). Disrupting protein-protein inter-
actions with non-peptidic, small molecule alpha-helix mimetics. Curr. Opin.
Chem. Biol. 14, 341–346.
Davis, J.M., Tsou, L.K., and Hamilton, A.D. (2007). Synthetic non-peptide
mimetics of small alpha-helices. Chem. Soc. Rev. 36, 326–334.
Delaglio, F., Grzesiek, S., Vuister, G., Zhu, G., Pfeifer, J., and Bax, A. (1995).
NMRPipe: a multidimensional spectral processing system based on UNIX
pipes. J. Biomol. NMR 6, 277–293.
Ernst, J.T., Kutzki, O., Debnath, A.K., Jiang, S., Lu, H., and Hamilton, A.D.
(2002). Design of a protein surface antagonist based on alpha-helix mimicry:
inhibition of gp41 assembly and viral fusion. Angew. Chem. Int. Ed. Engl. 41,
278–281.
Ernst, J.T., Becerril, J., Park, H.S., Yin, H., and Hamilton, A.D. (2003). Design
and application of an alpha-helix-mimetic scaffold based on an oligoamide-
foldamer strategy: antagonism of the Bak BH3/Bcl-xL complex. Angew.
Chem. Int. Ed. Engl. 42, 535–539.
Goddard, T.D., and Kneller, D.G. Sparky 3. (University of California).
Hebda, J.A., Saraogi, I., Magzoub, M., Hamilton, A.D., and Miranker, A.D.
(2009). A peptidomimetic approach to targeting pre-amyloidogenic states in
type II diabetes. Chem. Biol. 16, 943–950.
Hebda, J.A., Magzoub, M., and Miranker, A.D. (2014). Small molecule
screening in context: lipid-catalyzed amyloid formation. Protein Sci. 24,
1341–1348.
Huang, C., Lin, C., Haataja, L., Gurlo, T., Butler, A.E., Rizza, R.A., and Butler,
P.C. (2007). High expression rates of human islet amyloid polypeptide induce69–378, March 19, 2015 ª2015 Elsevier Ltd All rights reserved 377
endoplasmic reticulum stressmediated beta-cell apoptosis, a characteristic of
humans with type 2 but not type 1 diabetes. Diabetes 56, 2016–2027.
Kayed, R., Head, E., Thompson, J.L., McIntire, T.M., Milton, S.C., Cotman,
C.W., and Glabe, C.G. (2003). Common structure of soluble amyloid oligomers
implies common mechanism of pathogenesis. Science 300, 486–489.
Laganowsky, A., Liu, C., Sawaya, M.R., Whitelegge, J.P., Park, J., Zhao, M.,
Pensalfini, A., Soriaga, A.B., Landau, M., Teng, P.K., et al. (2012). Atomic
view of a toxic amyloid small oligomer. Science 335, 1228–1231.
Last, N.B., and Miranker, A.D. (2013). Common mechanism unites membrane
poration by amyloid and antimicrobial peptides. Proc. Natl. Acad. Sci. USA
110, 6382–6387.
Last, N.B., Rhoades, E., and Miranker, A.D. (2011). Islet amyloid polypeptide
demonstrates a persistent capacity to disrupt membrane integrity. Proc.
Natl. Acad. Sci. USA 108, 9460–9465.
Magzoub, M., andMiranker, A.D. (2012). Concentration-dependent transitions
govern the subcellular localization of islet amyloid polypeptide. FASEB J. 26,
1228–1238.
Middleton, E.R., and Rhoades, E. (2010). Effects of curvature and composition
on a-synuclein binding to lipid vesicles. Biophys. J. 99, 2279–2288.
Nath, A., Miranker, A.D., and Rhoades, E. (2011). A membrane-bound antipar-
allel dimer of rat islet amyloid polypeptide. Angew. Chem. Int. Ed. Engl. 50,
10859–10862.
Prabhakaran, P., Barnard, A., Murphy, N.S., Kilner, C.A., Edwards, T.A., and
Wilson, A.J. (2013). Aromatic oligoamide foldamers with a ‘‘wet edge’’ as inhib-378 Chemistry & Biology 22, 369–378, March 19, 2015 ª2015 Elsevieitors of the a-helix-mediated p53/hDM2 protein-protein interaction. Eur. J.
Org. Chem. 2013, 3504–3512.
Saraogi, I., Hebda, J., Becerril, J., Estroff, L., Miranker, A., and Hamilton, A.
(2010). Synthetic alpha-helix mimetics as agonists and antagonists of islet
amyloid polypeptide aggregation. Angew. Chem. Int. Ed. Engl. 49, 736–739.
Sevcsik, E., Trexler, A.J., Dunn, J.M., and Rhoades, E. (2011). Allostery in a
disordered protein: oxidative modifications to a-synuclein act distally to regu-
late membrane binding. J. Am. Chem. Soc. 133, 7152–7158.
Singh, B.K., Cavalluzzo, C., Maeyerc, M.D., Debyserd, Z., Parmar, V.S., and
Eycken, E.V. (2009). Microwave-assisted silver (I)-mediated selective
O-alkylation of aromatic imidate systems. Synthesis 16, 2725–2728.
Williamson, J.A., andMiranker, A.D. (2007). Direct detection of transient alpha-
helical states in islet amyloid polypeptide. Protein Sci. 16, 110–117.
Williamson, J.A., Loria, J.P., and Miranker, A.D. (2009). Helix stabilization
precedes aqueous and bilayer-catalyzed fiber formation in islet amyloid poly-
peptide. J. Mol. Biol. 393, 383–396.
Wolfe, L.S., Calabrese, M.F., Nath, A., Blaho, D.V., Miranker, A.D., and Xiong,
Y. (2010). Protein-induced photophysical changes to the amyloid indicator
dye thioflavin T. Proc. Natl. Acad. Sci. USA 107, 16863–16868.
Yin, H., Lee, G., Park, H.S., Payne, G.A., Rodriguez, J.M., Sebti, S.M., and
Hamilton, A.D. (2005). Terphenyl-based helical mimetics that disrupt the
p53/HDM2 interaction. Angew. Chem. Int. Ed. Engl. 117, 2764–2767.r Ltd All rights reserved
